November 2003
1573
to rats, as demonstrated by an increase in [3H]MK-801 bind-
ing.14) We examined the effect of prior treatment with 3-NP
on the brain uptake of [11C]NPS 1506. As can be seen from
Fig. 2, pretreatment with 3-NP (20 mg/kg) given intraperi-
toneally 3 h prior to tracer injection did not produce any
change in the regional uptake in the hippocampus nor the
striatum.
ported in part by CREST of Japan Science and Technology
Corporation.
REFERENCES AND NOTES
1) Brauner-Osborne H., Egebjerg J., Nielsen E. O., Madsen U., Krogs-
gaard-Larsen P., J. Med. Chem., 43, 2609—2645 (2000).
2) Kemp J. A., Mckernan R. M., Nature Neurosci. Suppl., 5, 1039—1042
(2002).
In summary, the labeling of NPS 1506 with carbon-11 in
the N-methyl position was accomplished with high specific
activity and high radiochemical purity. [11C]NPS 1506 ad-
ministered in tracer doses readily crosses the BBB consistent
with its partition coefficient (log Pϭ3.81).15) It has been re-
ported that a number of NMDA receptor antagonists acting
at the glycine site cross the BBB very poorly, despite their
lack of dose-limiting side effects.16) The good access of NPS
1506 to brain tissue gives it an advantage as an effective ther-
apeutic agent over other antagonists. We could not prove that
the accumulation of [11C]NPS 1506 in rat and mouse brains
was due to the specific binding to NMDA receptor binding
sites. This could possibly result from both low in vitro affin-
ity for NMDA receptors and large non-specific bound frac-
tions, which might have masked the interaction with specific
binding sites. In the present work, no metabolite studies were
undertaken, and therefore whether the unspecific pattern of
brain distribution of [11C]NPS 1506 was due to radiolabeled
metabolites that might have been formed in brain or pene-
trate the BBB remains uncertain. The observed brain reten-
tion of radioactivity may be related mainly to the affinity of
[11C]NPS 1506 itself for high-capacity, nonspecific binding
sites in brain tissues, similar to the accumulation mechanism
proposed for other lipophilic amines such as N-isopropyl-4-
3) Moe S. T., Shimizu S. M., Smith D. L., Van Wagenen B. C., DelMar E.
G., Balandrin M. F., Chien Y. (E)., Raszkiewicz J. L., Artman L. D.,
Mueller A. L., Lobkovsky E., Clardy J., Bioorg. Med. Chem. Lett., 9,
1915—1920 (1999).
4) Moe S. T., Smith D. L., DelMar E. G., Shimizu S. M., Van Wagenen
B. C., Balandrin M. F., Chien Y. (E)., Raszkiewicz J. L., Artman L. D.,
White H. S., Mueller A. L., Bioorg. Med. Chem. Lett., 10, 2411—2415
(2000).
5) Mueller A. L., Artman L. D., Balandrin M. F., Brady E., Chien Y. (E).,
DelMar E. G., George K., Kierstead A., Marriott T. B., Moe S. T.,
Newman M. K., Raszkiewicz, J. L., Sanguinetti E. L., Van Wagenen B.
C., Wells D., Ann. N.Y. Acad. Sci., 890, 450—461 (1999).
6) Gibson R. E., Burns H. D., Hamill T. G., Eng W., Francis B. E., Ryan
C., Curr. Pharm. Design, 6, 973—989 (2000).
7) Suzuki K., Inoue O., Hashimoto K., Yamasaki T., Kuchiki M., Tamate
K., Appl. Radiat. Isot., 36, 971—976 (1985).
8) Moe S. T., Smith D. L., By K., Egan J. A., Filer C. N., J. Labelled
Compds. Radiopharm., 41, 535—543 (1998).
9) Okauchi T., Suhara T., Maeda J., Kawabe K., Obayashi S., Suzuki K.,
Synapse, 41, 87—95 (2001).
10) Griecok P. A., Bahsas A., J. Org. Chem., 52, 5746—5749 (1987).
11) Wong E. H. F., Knight A. R., Woodruff G. N., J. Neurochem., 50,
274—281 (1988).
12) Ferrarese C., Guidotti A., Costa E., Miletich R. S., Rice K. C., de
Costa B. R., Fulham M. J., Di Chiro G., Neuropharmacol., 30, 899—
905 (1991).
13) Chen N., Luo T., Raymond L. A., J. Neurosci., 19, 6844—6854 (1999)
and references cited therein.
[
123I]-iodoamphetamine.17) Further experiments are necessary
14) Wüllner U., Young A. B., Penney J. B., Beal M. F., J. Neurochem., 63,
1772—1781 (1994).
to characterize the in vivo behavior of NPS 1506.
15) Calculated value using Advanced Chemistry Development (ACD)
Software Solaris V4.67, which is shown in STN databases.
16) Danysz W., Parsons C. G., Pharmacol. Rev., 50, 597—664 (1998).
17) Winchell H. S., Horst W. D., Braun L., Oldendorf W. H., Hattner R.,
Parker H., J. Nucl. Med., 21, 947—952 (1980).
Acknowledgments We thank the cyclotron crew of the
National Institute of Radiological Sciences for their help in
the 11C production of this works. This work has been sup-